FDA raps Biogen's plan to track MS drug's safety
Still analysts expect agency will approve return to the market
A day before the start of a crucial Food and Drug Administration review of the multiple sclerosis drug Tysabri, the agency released a report criticizing plans by drug makers Biogen Idec Inc. and Elan Corp. PLC to monitor the use of the drug and track the health of patients. (Full article: 741 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
